Jul. 12 at 6:29 PM
$MNKD --MiniMed is becoming a reality with separation from Medtronic as a stand alone core business with a near future IPO; current revenue for their diabetes space is
$2.5B. This is announced just before the anniversary of Al Mann's 7/28/2004 IPO of MNKD. Is this separation timing associated with Afrezza which just might be the primary driver for this split within Medtronic? Afrezza would be the ONLY non instrumental piece of Medtronic and being so would certainly justify its own P&L which would either be a winner like Alfred's pump has been or a total
$DRAG as its been for US. Why would Medtronic split off this business segment unless something BIG was coming, something new, that mandates "all hands on deck" --something like Afrezza that offers a complete response in all aspects of the treatment of diabetes?
